NO20002412L - Method of treating tumors and tumor cells using ex vivo activated T cells - Google Patents

Method of treating tumors and tumor cells using ex vivo activated T cells

Info

Publication number
NO20002412L
NO20002412L NO20002412A NO20002412A NO20002412L NO 20002412 L NO20002412 L NO 20002412L NO 20002412 A NO20002412 A NO 20002412A NO 20002412 A NO20002412 A NO 20002412A NO 20002412 L NO20002412 L NO 20002412L
Authority
NO
Norway
Prior art keywords
cells
treating tumors
vivo activated
tumor cells
vivo
Prior art date
Application number
NO20002412A
Other languages
Norwegian (no)
Other versions
NO20002412D0 (en
Inventor
David N Liebowitz
Carl June
Original Assignee
Arch Dev Corp
Jackson H M Found Military Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Dev Corp, Jackson H M Found Military Med filed Critical Arch Dev Corp
Publication of NO20002412D0 publication Critical patent/NO20002412D0/en
Publication of NO20002412L publication Critical patent/NO20002412L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Det er tilveiebrakt nye fremgangsmåter for modulering av en immunrespons ved anvendelse av behandling med T-celler som behandles ex vivo. Oppfinnelsen tilveiebringer en løsning på problemene som angår behandling av forskjellige sykdommer, spesielt sykdommer med malign beskaffenhet. Oppfinnelsen tilveie- bringer dessuten fremgangsmåter for behandling av sykdommer av ikke-malign beskaffenhet, ved modulering av et pattedyrs immunrespons.New methods have been provided for modulating an immune response using treatment with T cells treated ex vivo. The invention provides a solution to the problems related to the treatment of various diseases, especially diseases of a malignant nature. The invention further provides methods for treating diseases of non-malignant nature by modulating a mammalian immune response.

NO20002412A 1997-11-10 2000-05-09 Method of treating tumors and tumor cells using ex vivo activated T cells NO20002412L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6503197P 1997-11-10 1997-11-10
PCT/US1998/023954 WO1999024045A1 (en) 1997-11-10 1998-11-10 Methods for treatment of tumors and tumor cells using ex vivo activated t cells

Publications (2)

Publication Number Publication Date
NO20002412D0 NO20002412D0 (en) 2000-05-09
NO20002412L true NO20002412L (en) 2000-07-07

Family

ID=22059894

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002412A NO20002412L (en) 1997-11-10 2000-05-09 Method of treating tumors and tumor cells using ex vivo activated T cells

Country Status (6)

Country Link
EP (1) EP1030674A1 (en)
JP (1) JP2001522806A (en)
AU (1) AU1395499A (en)
CA (1) CA2309206A1 (en)
NO (1) NO20002412L (en)
WO (1) WO1999024045A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7718196B2 (en) 2001-07-02 2010-05-18 The United States Of America, As Represented By The Department Of Health And Human Services Rapamycin-resistant T cells and therapeutic uses thereof
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
TW200502391A (en) * 2003-05-08 2005-01-16 Xcyte Therapies Inc Generation and isolation of antigen-specific t cells
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US7592431B2 (en) 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
CA2555714C (en) 2004-02-26 2013-12-03 Immunovative Therapies, Ltd. Methods for preparing t-cells for cell therapy
RU2281783C1 (en) * 2005-04-06 2006-08-20 ГОУ ВПО "Красноярская государственная медицинская академия Министерства здравоохранения РФ" Prophylaxis of postoperative pyogenic/septic accidents in patients suffering from rectal cancer
JP2010032444A (en) * 2008-07-30 2010-02-12 Olympus Corp Living tissue treatment device
BR112013028285A2 (en) 2011-05-03 2017-01-10 Immunovative Therapies Ltd il-12 induction using immunotherapy
WO2012151266A1 (en) 2011-05-03 2012-11-08 Michael Har-Noy Methods for handling biological drugs containing living cells
JP6994021B2 (en) * 2016-08-26 2022-01-14 ジュノー セラピューティクス インコーポレイテッド How to count the particles present in a cell composition
DK3644728T3 (en) 2017-06-28 2022-10-31 Sci Group As FREEZING OF BIOLOGICAL MATERIAL
MA52114A (en) 2018-02-28 2021-01-06 Juno Therapeutics Inc METHODS FOR DETECTION OF PARTICLES PRESENT IN A CELLULAR COMPOSITION

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU617295B2 (en) * 1986-11-13 1991-11-28 Sloan-Kettering Institute For Cancer Research Compositions and method for treatment of cancer using monoclonal antibody against gd3 ganglioside together with il-2
EP1488805A2 (en) * 1992-04-07 2004-12-22 The Regents of the University of Michigan CD28 pathway immunoregulation
ATE293686T1 (en) * 1993-06-04 2005-05-15 Us Navy METHOD FOR SELECTIVELY STIMULATING T-CELL PROLIFERATION.
CA2227327A1 (en) * 1995-07-25 1997-02-13 Celltherapy, Inc. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease

Also Published As

Publication number Publication date
EP1030674A1 (en) 2000-08-30
AU1395499A (en) 1999-05-31
WO1999024045A1 (en) 1999-05-20
NO20002412D0 (en) 2000-05-09
JP2001522806A (en) 2001-11-20
CA2309206A1 (en) 1999-05-20

Similar Documents

Publication Publication Date Title
NO20002412L (en) Method of treating tumors and tumor cells using ex vivo activated T cells
DK0986382T3 (en) RAF kinase inhibitors
NO974275L (en) Method of treating tumors
DE69830072D1 (en) RADIOACTIVE COMPOSITIONS FOR THE TREATMENT OF PROSTATE TUMORS
ATE280619T1 (en) ELECTROMAGNETIC RADIATION THERAPY
EA199800391A1 (en) Inhibition of tumor growth by antisense oligonucleotides to IL-8 and IL-8 receptor
MY121548A (en) Compounds and methods for the treatment of cancer
EA200000220A1 (en) COMBINATION OF TYROSINKINASE INHIBITOR AND CHEMICAL STERILIZATION FOR TREATMENT OF PROSTATE GLAND
ATE378014T1 (en) SYSTEM FOR TREATING ABNORMAL TISSUE IN THE HUMAN ESOPHAUS
GR20010300007T1 (en) Inhibition of raf kinase using substituted heterocyclic ureas
EA200100573A1 (en) APPLICATION OF CYCLOOXIGENASE-2 INHIBITOR, MATRIC METALLOPROTEINASE INHIBITOR, ANTI-TUMOR MEDICINE, AND OPTIONAL IRRADIATION AS A COMBINED METHOD OF TREATING THE NEO.
ATE260666T1 (en) CELLULAR VACCINE AND USE THEREOF FOR THE TREATMENT OF MALIGNANT SOLID TUMORS
ATE277515T1 (en) METHOD FOR TREATING PIGMENTED CANCER CELLS BY PHOTODYNAMIC THERAPY
NO974824D0 (en) Arteriovenous and venous transplant treatments, procedures and mixtures
DK0912192T3 (en) Administration of GM-CSF to treat brain tumors and prevent the recurrence of such tumors
ATE402713T1 (en) GENETICALLY MANIPULATED HERPES VIRUSES FOR THE TREATMENT OF TUMORS
NO965395D0 (en) Human monoclonal antibodies specific for cell cycle-independent glioma surface antigen
ES2187648T3 (en) METHOD FOR THE ADMINISTRATION OF PHARMACOS FOR GENE THERAPY.
ATE392210T1 (en) METHODS OF TREATING SOLID TUMORS AND METASTASIS USING GENE THERAPY
DE69912743D1 (en) TREATMENT OF FOLLICULAR LYMPHOMAS USING INHIBITORS OF THE LYMPHOTOXIN (LT) ACTIVATION WAY
ATE179594T1 (en) USE OF ETHISTERONE FOR THE TOPICAL TREATMENT OF ACNE OR ANDROGENETIC ALOPECIA
Karu et al. Biological action of low-intensity monochromatic light in the visible range
SU619185A1 (en) Method of treating small pelvis malignant tumors
ATE291620T1 (en) MAMMARY CARCINOMA-ASSOCIATED GENE
EA199800058A1 (en) METHOD OF TREATMENT OF BENEFICIAL PROSTATE HYPERPLASIA, A MEDICAL FORM FOR THE TREATMENT OF BENEFICIAL HYPERPLASIA CONTAINING MELATONIN AGONIST

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application